In particular, RMC-6236 presented an ORR of 25–29% in pretreated patients with KRAS mutant PDAC, while the most common TRAEs were skin/mucosal toxicity (rash, paronychia, mucosal inflammation, peripheral edema, and stomatitis) and gastrointestinal events (diarrhea, nausea, vomiting, and decreased appetite). The gene discussed is KRAS; the disease is paronychia.